Immunomedics (IMMU) Reports Q1 Loss of $0.34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Immunomedics Announces First Quarter Fiscal 2019 Results and Provides Corporate Update
November 7, 2018 4:05 PM ESTStrategic Manufacturing Partnership Entered into with Samsung BioLogics to Provide Anticipated Long-Term Supply of Sacituzumab Govitecan
Commercial Launch Preparations Nearing Completion with 50 Sales Representatives Recruited and in Training
Clinical Collaboration Agreement with AstraZeneca/MedImmune Expanded to Include Non-Small Cell Lung Cancer
MORRIS PLAINS, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Â Immunomedics, Inc.,... More
